首页> 美国卫生研究院文献>World Journal of Virology >Human immunodeficiency virus/acquired immune deficiency syndrome: Using drug from mathematical perceptive
【2h】

Human immunodeficiency virus/acquired immune deficiency syndrome: Using drug from mathematical perceptive

机译:人类免疫缺陷病毒/后天免疫缺陷综合症:使用数学知性药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Entry of acquired immune deficiency syndrome virus into the host immune cell involves the participation of various components of host and viral cell unit. These components may be categorized as attachment of the viral surface envelope protein subunit, gp120, to the CD4+ receptor and chemokine coreceptors, CCR5 and CXCR4, present on T cell surface. The viral fusion protein, gp41, the second cleaved subunit of Env undergoes reconfiguration and the membrane fusion reaction itself. Since the CD4+ T cell population is actively involved; the ultimate outcome of human immunodeficiency virus infection is total collapse of the host immune system. Mathematical modeling of the stages in viral membrane protein-host cell receptor-coreceptor interaction and the effect of antibody vaccine on the viral entry into the susceptible host cell has been carried out using as impulsive differential equations. We have studied the effect of antibody vaccination and determined analytically the threshold value of drug dosage and dosing interval for optimum levels of infection. We have also investigated the effect of perfect adherence of drug dose on the immune cell count in extreme cases and observed that systematic drug dosage of the immune cells leads to longer and improved lives.
机译:获得性免疫缺陷综合症病毒进入宿主免疫细胞涉及宿主和病毒细胞单位的各种成分的参与。这些成分可归类为病毒表面包膜蛋白亚基gp120与T细胞表面上存在的CD4 + 受体和趋化因子共受体CCR5和CXCR4的结合。病毒融合蛋白gp41(Env的第二个被切割的亚基)经过重新构型和膜融合反应本身。由于CD4 + T细胞群体活跃参与;人类免疫缺陷病毒感染的最终结果是宿主免疫系统完全崩溃。已经使用脉冲微分方程进行了病毒膜蛋白-宿主细胞受体-共受体相互作用的阶段的数学建模以及抗体疫苗对病毒进入易感宿主细胞的影响。我们已经研究了抗体疫苗接种的效果,并通过分析确定了最佳感染水平的药物剂量阈值和给药间隔。我们还研究了在极端情况下完全遵守药物剂量对免疫细胞计数的影响,并观察到免疫细胞的系统药物剂量可以延长寿命并改善寿命。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号